Cargando…

Polypharmacy in Older Adults with Alzheimer’s Disease

The number of patients with Alzheimer’s disease is increasing annually. Most of these patients are older adults with comorbid physical illnesses, which means that they are often treated with a combination of medications for the disease they have and those for Alzheimer’s disease. Thus, older adults...

Descripción completa

Detalles Bibliográficos
Autores principales: Esumi, Satoru, Ushio, Soichiro, Zamami, Yoshito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608980/
https://www.ncbi.nlm.nih.gov/pubmed/36295605
http://dx.doi.org/10.3390/medicina58101445
_version_ 1784818902482550784
author Esumi, Satoru
Ushio, Soichiro
Zamami, Yoshito
author_facet Esumi, Satoru
Ushio, Soichiro
Zamami, Yoshito
author_sort Esumi, Satoru
collection PubMed
description The number of patients with Alzheimer’s disease is increasing annually. Most of these patients are older adults with comorbid physical illnesses, which means that they are often treated with a combination of medications for the disease they have and those for Alzheimer’s disease. Thus, older adults with Alzheimer’s disease are potentially at risk for polypharmacy. In addition, the drug interactions between Alzheimer’s disease medications and those for the treatment of physical illnesses may reduce their efficacy and increase side effects. This article reviews polypharmacy and drug interactions in elderly patients with Alzheimer’s disease, with a focus on psychotropic drugs.
format Online
Article
Text
id pubmed-9608980
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96089802022-10-28 Polypharmacy in Older Adults with Alzheimer’s Disease Esumi, Satoru Ushio, Soichiro Zamami, Yoshito Medicina (Kaunas) Review The number of patients with Alzheimer’s disease is increasing annually. Most of these patients are older adults with comorbid physical illnesses, which means that they are often treated with a combination of medications for the disease they have and those for Alzheimer’s disease. Thus, older adults with Alzheimer’s disease are potentially at risk for polypharmacy. In addition, the drug interactions between Alzheimer’s disease medications and those for the treatment of physical illnesses may reduce their efficacy and increase side effects. This article reviews polypharmacy and drug interactions in elderly patients with Alzheimer’s disease, with a focus on psychotropic drugs. MDPI 2022-10-13 /pmc/articles/PMC9608980/ /pubmed/36295605 http://dx.doi.org/10.3390/medicina58101445 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Esumi, Satoru
Ushio, Soichiro
Zamami, Yoshito
Polypharmacy in Older Adults with Alzheimer’s Disease
title Polypharmacy in Older Adults with Alzheimer’s Disease
title_full Polypharmacy in Older Adults with Alzheimer’s Disease
title_fullStr Polypharmacy in Older Adults with Alzheimer’s Disease
title_full_unstemmed Polypharmacy in Older Adults with Alzheimer’s Disease
title_short Polypharmacy in Older Adults with Alzheimer’s Disease
title_sort polypharmacy in older adults with alzheimer’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608980/
https://www.ncbi.nlm.nih.gov/pubmed/36295605
http://dx.doi.org/10.3390/medicina58101445
work_keys_str_mv AT esumisatoru polypharmacyinolderadultswithalzheimersdisease
AT ushiosoichiro polypharmacyinolderadultswithalzheimersdisease
AT zamamiyoshito polypharmacyinolderadultswithalzheimersdisease